title: A sensitive, reproducible and objective immunofluorescence analysis method of dystrophin in individual fibers in samples from patients with duchenne muscular dystrophy.
abstract: Duchenne muscular dystrophy (DMD) is characterized by the absence or reduced levels of dystrophin expression on the inner surface of the sarcolemmal membrane of muscle fibers. Clinical development of therapeutic approaches aiming to increase dystrophin levels requires sensitive and reproducible measurement of differences in dystrophin expression in muscle biopsies of treated patients with DMD. This, however, poses a technical challenge due to intra- and inter-donor variance in the occurrence of revertant fibers and low trace dystrophin expression throughout the biopsies. We have developed an immunofluorescence and semi-automated image analysis method that measures the sarcolemmal dystrophin intensity per individual fiber for the entire fiber population in a muscle biopsy. Cross-sections of muscle co-stained for dystrophin and spectrin have been imaged by confocal microscopy, and image analysis was performed using Definiens software. Dystrophin intensity has been measured in the sarcolemmal mask of spectrin for each individual muscle fiber and multiple membrane intensity parameters (mean, maximum, quantiles per fiber) were calculated. A histogram can depict the distribution of dystrophin intensities for the fiber population in the biopsy. This method was tested by measuring dystrophin in DMD, Becker muscular dystrophy, and healthy muscle samples. Analysis of duplicate or quadruplicate sections of DMD biopsies on the same or multiple days, by different operators, or using different antibodies, was shown to be objective and reproducible (inter-assay precision, CV 2-17% and intra-assay precision, CV 2-10%). Moreover, the method was sufficiently sensitive to detect consistently small differences in dystrophin between two biopsies from a patient with DMD before and after treatment with an investigational compound.
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Chantal
authors.initials: C
authors.lastname: Beekman
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Jessica A
authors.initials: JA
authors.lastname: Sipkens
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Janwillem
authors.initials: J
authors.lastname: Testerink
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Stavros
authors.initials: S
authors.lastname: Giannakopoulos
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Dyonne
authors.initials: D
authors.lastname: Kreuger
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Judith C
authors.initials: JC
authors.lastname: van Deutekom
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Giles V
authors.initials: GV
authors.lastname: Campion
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Sjef J
authors.initials: SJ
authors.lastname: de Kimpe
authors.affiliation: Prosensa Therapeutics BV, Leiden, the Netherlands.
authors.forename: Afrodite
authors.initials: A
authors.lastname: Lourbakos
mesh_terms: D001706:Biopsy; D016189:Dystrophin / Q000378:metabolism*; D005455:Fluorescent Antibody Technique / Q000379:methods*; D006801:Humans; D018485:Muscle Fibers, Skeletal / Q000378:metabolism* / Q000473:pathology; D020388:Muscular Dystrophy, Duchenne / Q000378:metabolism* / Q000473:pathology; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D016189:Dystrophin